The medication, formerly known as KarXT, is the first antipsychotic medication to target cholinergic receptors rather than dopamine receptors, according to a Sept. 26 news release from the agency.

In a previous article, I made the case that little has changed within the antipsychotic drug landscape over the past 70 years since the only effective medications for the treatment of schizophrenia ...

A new study published in Nature Communications reveals that a brain chemical called acetylcholine can directly trigger the ...

Add Yahoo as a preferred source to see more of our stories on Google. On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.